Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026

Drug Farm announced it will present findings from its Phase 1b study of DF-003, a first-in-class ALPK1 inhibitor, at ARVO 2026. The study showed improvements in visual function and neurological symptoms in patients with ROSAH syndrome. Key findings include reductions in optic disc swelling and gains in visual acuity. DF-003 was well tolerated, with no serious adverse events. The company plans to advance DF-003 into a Phase 3 trial to further evaluate its efficacy and safety. The drug has received multiple FDA designations for its potential in treating ROSAH syndrome and other diseases.